Oral administration of the dopamine prodrug docarpamine shortens need for drip infusion of dopamine in patients with low cardiac output syndrome after cardiac surgery

Thoracic and Cardiovascular Surgeon

Volumn 47, Issue 6, 1999, Pages 352-356

  Matsubayashi, Keiji ^a   Ueda, Y ^a   Ogino, H ^a   Sugita, T ^a   Sakakibara, Y ^a   Matsuyama, K ^a   Nomoto, T ^a  

^a TENRI HOSPITAL   (Japan)

Author keywords

Docarpamine; Dopamine prodrug; Low cardiac output syndrome; Post cardiac surgery

Indexed keywords

CATECHOLAMINE DERIVATIVE; DOCARPAMINE; DOPAMINE; PRODRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; FORWARD HEART FAILURE; HEART OUTPUT; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART SURGERY; HEMODYNAMICS; HUMAN; INFUSION SYSTEM; KIDNEY BLOOD FLOW; MALE; POSTOPERATIVE CARE; PRIORITY JOURNAL; WEANING;

EID: 0033373993     PISSN: 01716425     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1013173     Document Type: Article

References (16)

1. Yamaguchi I, Nishiyama S, Akimoto Y, Yoshikawa M, Nakajima H. A novel orally active dopamine prodrug TA-870. I. Renal and cardiovascular effects and plasma levels of free dopamine in dogs and rats. J Cardiovasc Pharmacol. 1989;13 : 879-86.
2. Yoshikawa M, Nishiyama S, Endo H, Togo H, Takaiti O. First pass metabolism and in vitro metabolism of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxy-carbonyl)dopamine (TA-870) in dogs. Drug Metab Dispos. 1991;19 : 960-5.
3. Nishiyama S, Yamaguchi I. A novel orally active dopamine prodrug TA-870. V. Natriuretic and positive inotropic effects in rats: an assessment after chronic administration. J Cardiovasc Pharmacol. 1991;17 : 768-77.
4. Nishiyama S, Yamaguchi I, Akimoto Y, Yoshikawa M, Nakajima H. A novel orally active dopamine prodrug TA-870. II. Evidence that TA-870 is a dopamine prodrug. J Cardiovasc Pharmacol. 1989;14 : 175-83.
5. Nishiyama S, Yamaguchi I, Akimoto Y, Yoshikawa M, Nakajima H. A novel orally active dopamine prodrug TA-870. III. Positive inotropic effect and cardiorenal selectivity in anesthetized dogs. J Cardiovasc Pharmacol. 1990;15 : 283-90.
6. Nishiyama S, Yoshikawa M, Yamaguchi I. A novel orally active dopamine (DA) prodrug TA-870. IV Renal vasodilatory and negative chronotropic effects in anesthetized dogs: influence of DA1 and DA2 dopamine receptor selective antagonists. J Cardiovasc Pharmacol. 1991;17 : 560-7.
7. Goldberg LI. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev. 1972;24 : 1-29.
8. Goldberg LI. The role of dopamine receptors in the treatment of congestive heart failure. J Cardiovasc Pharmacol. 1989;14 (Suppl. 5) : S19-27.
9. Goldberg LI, MacDonald RH, Zimmerman AM. Sodium diuresis produced by dopamine in patients with congestive heart failure. N Engl J Med. 1963;269 : 1060-4.
10. Goldberg LI, Rajfer SI. Dopamine receptors: applications in clinical cardiology. Circulation. 1985;72 : 245-8.
11. Loeh HS, Winslow EBJ, Rahimtoola SH, Rosen KM, Gunnar RM. Acute hemodynamic effects of dopamine in patient with shock. Circulation. 1971;44 : 163-73.
12. MacCannel KL, McNay JL, Meyer MB, Goldberg LI. Dopamine in the treatment of hypotension and shock. N Engl J Med. 1966;275 : 1389-98.
13. Merits I, Anderson J, Senders RC. Species differences in the metabolism of orally administered dopamine 14C and N-alanyl-dopamine-14C. Drug Metab Dispos. 1971;1 : 691-7.
14. Murata K, Noda K, Kohno K, Samejima M. Pharmacokinetic analysis of absorption and metabolism of dopamine and a dopamine prodrug in dogs Biopharm Drug Dispos. 1990;11 : 149-56.
15. Tanaka K, Munakata K, Takano T, Nagasawa K, Hayakawa H, Okumura H. The phase I study of KW-3160 (orally active dopamine). Jpn Clin Pharmacol Ther. 1985;16 : 259-60.
16. Simizu K. Clinical evaluation of oral dopamine (docarpamine) in patients with low cardiac output syndrome after cardiac surgery. In Japanese. J N Remed Clinics. 1996;45 : 1987-94.